AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28578704 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine Phospholipids (MPL) supplementation at 0.3 g of n-3-fatty acids per day for six weeks
Number of subjects: 60
Study 28578704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation at 0.3 g of n-3-fatty acids per day for six weeks
Number of subjects: 60
Study 24722788 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system
Number of subjects: 38
Study 24722788 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 38
Study 23849948 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with ARWMC score of 7 or more
Number of subjects: 1036
Study 23849948 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with ARWMC score of less than 7
Number of subjects: 1036
Study 23849948 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy with ARWMC score of 7 or more
Number of subjects: 1036
Study 23849948 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery stenting compared to carotid endarterectomy in patients with ARWMC score of 7 or more
Number of subjects: 1036
Study 23849948 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy with ARWMC score of less than 7
Number of subjects: 1036
Study 20679165 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month mentoring and skills group program
Number of subjects: 156
Study 20679165 — intervention group
Group type: COMPARATOR
Intervention: Control group (assessment only)
Number of subjects: 156
Study 19142359 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery without extracorporeal circulation (WECC)
Number of subjects: 259
Study 19142359 — intervention group
Group type: COMPARATOR
Intervention: Surgery with extracorporeal circulation (SECC)
Number of subjects: 259
Study 16344336 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (75 mg hydroalcoholic gel applied daily)
Number of subjects: 38
Study 16344336 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 38
Study 14583904 — intervention group
Group type: COMPARATOR
Intervention: Increased left ventricular wall thickness (LVH) in group A (30%) versus group B (18%)
Number of subjects: 562
Study 14583904 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality rate in group A (17%) versus group B (22%)
Number of subjects: 562
Study 14583904 — intervention group
Group type: COMPARATOR
Intervention: Odds of having LVH in group A versus group B
Number of subjects: 562
Study 14583904 — intervention group
Group type: COMPARATOR
Intervention: Calculated mean LV mass
Number of subjects: 562
Study 10672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions supported by randomized controlled trials
Number of subjects: 197
Study 10672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions supported by consensus among experienced clinicians
Number of subjects: 197
Study 10672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in patients with cardiac diagnoses
Number of subjects: 197
Study 10672136 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions in patients with other circulatory diagnoses
Number of subjects: 197
Study 7618543 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional turbo spin-echo MR cholangiopancreatography
Number of subjects: 30
Study 7618543 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic or percutaneous cholangiopancreatography
Number of subjects: 30
Study 2189617 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (20, 40, 80 mg/day, once or twice daily)
Number of subjects: 270
Study 2189617 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (10-40 mg/day, once or twice daily)
Number of subjects: 270
Study 2189617 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (10, 20, and 40 mg/day, with optional titration)
Number of subjects: 270
Study 2189617 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 270
Study 2189617 — intervention group
Group type: COMPARATOR
Intervention: Quinapril
Number of subjects: 270
Study 666189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cholangiography (official reading)
Number of subjects: 47
Study 666189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cholangiography (blind reading)
Number of subjects: 47
Study 666189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic cholangiography
Number of subjects: 47
Study 31136543 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional training (TT)
Number of subjects: 35
Study 31136543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster training (CT)
Number of subjects: 35
Study 31136543 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 31151199 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil supplementation (400 mg EPA and DHA per day)
Number of subjects: 267
Study 31151199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 267
Study 31151199 — intervention group
Group type: EXPERIMENTAL
Intervention: Krill oil supplementation (800 mg EPA + DHA per day)
Number of subjects: 267
Study 27752842 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia assessment
Number of subjects: 88
Study 27752842 — intervention group
Group type: COMPARATOR
Intervention: Text-based assessment
Number of subjects: 88
Study 27752842 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia assessment for respiratory questions
Number of subjects: 88
Study 27752842 — intervention group
Group type: COMPARATOR
Intervention: Text-based assessment for respiratory questions
Number of subjects: 88
Study 27752842 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia assessment for dermatology questions
Number of subjects: 88
Study 27752842 — intervention group
Group type: COMPARATOR
Intervention: Text-based assessment for dermatology questions
Number of subjects: 88
Study 27752842 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ITE scores with text-based scores
Number of subjects: 88
Study 27752842 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ITE scores with multimedia scores
Number of subjects: 88
Study 26016823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 30
Study 26016823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immediate LVRS)
Number of subjects: 30
Study 23158959 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 529
Study 23158959 — intervention group
Group type: COMPARATOR
Intervention: Non-ECT
Number of subjects: 529
Study 21513473 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Cellular Construct (LCC)
Number of subjects: 96
Study 21513473 — intervention group
Group type: COMPARATOR
Intervention: Free Gingival Graft (FGG)
Number of subjects: 96
Study 18291168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-seeded collagen matrix
Number of subjects: 20
Study 18291168 — intervention group
Group type: COMPARATOR
Intervention: No matrix
Number of subjects: 20
Study 17183729 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose simvastatin (80 mg)
Number of subjects: 0
Study 17183729 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (40 mg)
Number of subjects: 0
Study 17183729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14505903 — intervention group
Group type: EXPERIMENTAL
Intervention: FLUAD
Number of subjects: 301
Study 14505903 — intervention group
Group type: COMPARATOR
Intervention: Fluzone
Number of subjects: 301
Study 10750576 — intervention group
Group type: EXPERIMENTAL
Intervention: Neridronate (50 mg iv every 2 months for a year)
Number of subjects: 87
Study 10750576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 87
Study 9117754 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Amlexanox oral paste
Number of subjects: 1335
Study 9117754 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1335
Study 8362449 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) once weekly
Number of subjects: 312
Study 8362449 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil (PROG) daily
Number of subjects: 312
Study 8362449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Chloroquine and Proguanil (CQ + PROG)
Number of subjects: 312
Study 8362449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 312
Study 3095780 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective antimicrobial modulation of the intestinal flora (SAM) with trimethoprim-sulfamethoxazole
Number of subjects: 65
Study 3095780 — intervention group
Group type: COMPARATOR
Intervention: Total antibiotic decontamination (TAD) with gentamicin, vancomycin and colimycin
Number of subjects: 65
Study 30854705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine dermis-derived collagen membrane (test group)
Number of subjects: 36
Study 30854705 — intervention group
Group type: COMPARATOR
Intervention: Bio-Gide (control group)
Number of subjects: 36
Study 29492615 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral GR3027
Number of subjects: 0
Study 29492615 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg oral GR3027
Number of subjects: 0
Study 29492615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26383833 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAID (web-based breast reconstruction decision support aid)
Number of subjects: 55
Study 26383833 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet (Cancer Support Community's Frankly Speaking About Cancer: Breast Reconstruction)
Number of subjects: 55
Study 24898643 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil + Choline Alphoscerate
Number of subjects: 113
Study 24898643 — intervention group
Group type: COMPARATOR
Intervention: Donepezil + Placebo
Number of subjects: 113
Study 23035890 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic strategies
Number of subjects: 197910
Study 23035890 — intervention group
Group type: COMPARATOR
Intervention: Faecal tests
Number of subjects: 197910
Study 23035890 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT (Fecal Immunochemical Test)
Number of subjects: 197910
Study 23035890 — intervention group
Group type: COMPARATOR
Intervention: g-FOBT (guaiac-based fecal occult blood test)
Number of subjects: 197910
Study 20360151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Counts intervention (lifestyle change classes for eight weeks, goal-setting, and telephone follow-up for three months)
Number of subjects: 187
Study 20360151 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (equivalent amount of contact in classes on general disease-related information and health education topics, unstructured follow-up phone calls)
Number of subjects: 187
Study 20360151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Counts intervention
Number of subjects: 187
Study 20360151 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 187
Study 18552672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequestrectomy
Number of subjects: 174
Study 18552672 — intervention group
Group type: COMPARATOR
Intervention: Control (standard microsurgical treatment)
Number of subjects: 174
Study 15855347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234
Study 15855347 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3234
Study 15855347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 12455074 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 78
Study 12455074 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 10348768 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B in 5% dextrose
Number of subjects: 61
Study 10348768 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B in fat emulsion (Intralipid)
Number of subjects: 61
Study 10348768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 8769206 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral therapy
Number of subjects: 0
Study 1385658 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity program with a behavioral therapy approach (n = 51)
Number of subjects: 103
Study 1385658 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (Control group, n = 52)
Number of subjects: 103
Study 6093960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 100 mg
Number of subjects: 120
Study 6093960 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg
Number of subjects: 120
Study 6093960 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 120
Study 30272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Active V1 subcutaneous trigeminal nerve stimulation (sTNS) as adjuvant to medical therapy
Number of subjects: 20
Study 30272245 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 30272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sTNS
Number of subjects: 20
Study 30272245 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label phase following the initial trial
Number of subjects: 20
Study 28751267 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice water test (4C)
Number of subjects: 40
Study 28751267 — intervention group
Group type: COMPARATOR
Intervention: Warm water test (36C)
Number of subjects: 40
Study 26018041 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic Memory Advanced Reasoning Training (SMART)
Number of subjects: 60
Study 26018041 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Workshop (BHW)
Number of subjects: 60
Study 24799513 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater total leisure-time activity
Number of subjects: 985
Study 24799513 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater walking distance
Number of subjects: 985
Study 24799513 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater walking pace
Number of subjects: 985
Study 22417137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 HQID
Number of subjects: 4
Study 22417137 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 HQID
Number of subjects: 4
Study 22417137 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 and Phase 2 HQID
Number of subjects: 4
Study 20096909 — intervention group
Group type: EXPERIMENTAL
Intervention: Praneem polyherbal tablet
Number of subjects: 100
Study 20096909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17868127 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 56
Study 17868127 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa - binge eating purging subtype (AN-BP)
Number of subjects: 56
Study 17868127 — intervention group
Group type: COMPARATOR
Intervention: Bulimia nervosa (BN)
Number of subjects: 56
Study 17868127 — intervention group
Group type: COMPARATOR
Intervention: Major depression (DEP)
Number of subjects: 56
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group with protective factors (BMI < 25 kg/m(2), waist-hip ratio < 0.85 for women and 0.90 for men, never smoking, medium to high physical activity, light drinking, prudent dietary pattern)
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group with protective factors
Number of subjects: 1018
Study 16026378 — intervention group
Group type: COMPARATOR
Intervention: None of the protective factors
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: One protective factor
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Two protective factors
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Three protective factors
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Four protective factors
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Five protective factors
Number of subjects: 1018
Study 16026378 — intervention group
Group type: EXPERIMENTAL
Intervention: Six protective factors
Number of subjects: 1018
Study 12476932 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone, 20 mg twice daily
Number of subjects: 20
Study 12476932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10330639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injection of 0.5 mL lidocaine 1%
Number of subjects: 10
Study 8955574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 20
Study 8955574 — intervention group
Group type: EXPERIMENTAL
Intervention: Injective immunotherapy
Number of subjects: 20
Study 1836290 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mcg recombinant DNA yeast-derived hepatitis B vaccine
Number of subjects: 314
Study 1836290 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg recombinant DNA yeast-derived hepatitis B vaccine
Number of subjects: 314
Study 1836290 — intervention group
Group type: COMPARATOR
Intervention: Both doses (10 mcg and 20 mcg)
Number of subjects: 314
Study 7425396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (11 patients receiving injections for the first time)
Number of subjects: 51
Study 7425396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (20 patients already receiving injections)
Number of subjects: 51
Study 7425396 — intervention group
Group type: COMPARATOR
Intervention: Group III (20 control patients who did not receive any injections)
Number of subjects: 51
Study 31274231 — intervention group
Group type: EXPERIMENTAL
Intervention: E39 + GM-CSF vaccine (1000 μg)
Number of subjects: 51
Study 31274231 — intervention group
Group type: EXPERIMENTAL
Intervention: E39 + GM-CSF vaccine (<1000 μg)
Number of subjects: 51
Study 31274231 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study 31274231 — intervention group
Group type: EXPERIMENTAL
Intervention: E39 + GM-CSF vaccine (any dose)
Number of subjects: 51
Study 28696286 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin treatment (24 International Units, twice daily for 4 weeks)
Number of subjects: 32
Study 28696286 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 25282519 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks
Number of subjects: 331
Study 25282519 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly
Number of subjects: 331
Study 25282519 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks
Number of subjects: 331
Study 25282519 — intervention group
Group type: COMPARATOR
Intervention: Placebo monthly
Number of subjects: 331
Study 25076659 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based fortified complementary food and nutrition education (Cf)
Number of subjects: 292
Study 25076659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkle and nutrition education (Mp)
Number of subjects: 292
Study 25076659 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education alone (Ed)
Number of subjects: 292
Study 25076659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified complementary food (Cf)
Number of subjects: 292
Study 22931630 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide plus albumin
Number of subjects: 24
Study 22931630 — intervention group
Group type: COMPARATOR
Intervention: Furosemide alone
Number of subjects: 24
Study 22254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised fracture risk feedback based on bone mineral density (BMD)
Number of subjects: 0
Study 22254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self‐Management Course (OPSMC)
Number of subjects: 0
Study 22254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements
Number of subjects: 0
Study 22254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity change
Number of subjects: 0
Study 22254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving the OPSMC
Number of subjects: 0
Study 22254067 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of high fracture risk
Number of subjects: 0
Study 16893523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 163
Study 16893523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 16372516 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 70
Study 16372516 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 70
Study 16372516 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 70
Study 16372516 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (pooled data)
Number of subjects: 70
Study 12487013 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape intervention for sexual counseling after MI
Number of subjects: 0
Study 12487013 — intervention group
Group type: COMPARATOR
Intervention: Usual written and verbal instructions while hospitalized
Number of subjects: 0
Study 9807202 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 349
Study 9807202 — intervention group
Group type: COMPARATOR
Intervention: CMF regimen
Number of subjects: 349
Study 7510510 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia to T4-S5 in addition to general anaesthetic
Number of subjects: 16
Study 7510510 — intervention group
Group type: COMPARATOR
Intervention: Standardized general anaesthetic
Number of subjects: 16
Study 2660519 — intervention group
Group type: EXPERIMENTAL
Intervention: Muroctasin 100 micrograms
Number of subjects: 32
Study 2660519 — intervention group
Group type: EXPERIMENTAL
Intervention: Muroctasin 50 micrograms
Number of subjects: 32
Study 2660519 — intervention group
Group type: EXPERIMENTAL
Intervention: Muroctasin (both doses)
Number of subjects: 32
Study 29077862 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP requiring re-authorization of restricted antibiotics on day 3
Number of subjects: 166